Abstracts tagged "pregnancy"

Abstract Number: 2442 • 2016 ACR/ARHP Annual Meeting
Use of Nonsteroidal Anti-Inflammatory Drugs in Pregnant Women with Inflammatory Arthritis
Neda Amiri¹, Gretchen Bandoli², Diana L Johnson² and Christina D. Chambers², ¹Division of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pediatrics, University of California, San Diego, La Jolla, CA
Use of Nonsteroidal Anti-inflammatory Drugs in Pregnant Women with Inflammatory Arthritis Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are generally contraindicated in the third trimester of pregnancy…
Abstract Number: 2443 • 2016 ACR/ARHP Annual Meeting
Pregnancy Comorbidities and Outcomes in Psoriasis and Psoriatic Arthritis: A Prospective Cohort Study
Neda Amiri¹, Gretchen Bandoli² and Christina Chambers², ¹Division of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pediatrics, University of California, San Diego, La Jolla, CA
Pregnancy Comorbidities and Outcomes in Psoriasis and Psoriatic Arthritis: A Prospective Cohort Study Background/Purpose: While there is some evidence that women with psoriasis (Pso) and…
Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Mark Berman¹, Daphna Paran¹, Yonatan Wolman¹ and Ori Elkayam², ¹Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…
Abstract Number: 2519 • 2015 ACR/ARHP Annual Meeting
Pregnancy in Psoriatic Arthritis: A Case Series
Maria Mouyis¹, Clare Thornton¹, David Williams^2,3 and Ian Giles⁴, ¹Rheumatology, University College London Hospital, London, United Kingdom, ²Institute for Women’s Health, University College London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: It is recognised that active disease in women with inflammatory arthritis is associated with adverse pregnancy outcomes. Most studies however, have focussed upon patients…
Abstract Number: 2521 • 2015 ACR/ARHP Annual Meeting
Pregnancies in Patients with Long-Standing Rheumatoid Arthritis and Biologic DMARD Treatment: Course of Disease during Pregnancy and Pregnancy Outcomes
Anja Strangfeld¹, Dagmar Pattloch¹, Madlen Spilka², Bernhard Manger³, Brigitte Krummel-Lorenz⁴, Annett Gräßler⁵, Joachim Listing⁶ and Angela Zink^1,7, ¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatologist, Scientific Advisory Board, Erlangen, Germany, ⁴Rheumatologist, Frankfurt, Germany, ⁵Rheumatologist, Pirna, Germany, ⁶Epidemiologiy, German Rheumatism Research Center, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany
Background/Purpose: The assumption of spontaneous remission among pregnant women with rheumatoid arthritis (RA) is common. Nevertheless, prospectively collected data describing the course of disease activity…
Abstract Number: 2525 • 2015 ACR/ARHP Annual Meeting
Patterns and Secular Trends in Use of Immunosuppressive Agents during Pregnancy in Women with Rheumatologic Conditions
Rishi J. Desai¹, Krista Huybrechts², Brian Bateman², Sonia Hernandez-diaz³, Helen Mogun², Chandrasekar Gopalakrishnan⁴, Elisabetta Patorno⁴ and Seoyoung C. Kim⁵, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Systemic inflammatory conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) affect many women during their…
Abstract Number: 2528 • 2015 ACR/ARHP Annual Meeting
Utilization of Immune-Suppressive Medications during Pregnancy Among Women with Inflammatory Arthritis and Other Autoimmune Diseases
Jie Zhang^1,2, Jeffrey R. Curtis³, Fenglong Xie⁴, Melissa L. Mannion⁵, James D. Lewis^6,7, Megan E. B. Clowse⁸, Kenneth G. Saag³, Steven Bethard⁹, Jospeh Biggio⁹, Gerald McGwin⁹ and Timothy Beukelman¹⁰, ¹Epidemilogy, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Medicine, University of Pennsylvania, Philadelphia, PA, ⁸Clinical Rheumatologist, Duke University Medical Center, Durham, NC, ⁹UAB, Birmingham, AL, ¹⁰Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To examine difference in the prevalence of immunosuppressive medication use during pregnancy by type of autoimmune disease and by insurance (Medicaid versus commercial) in…
Abstract Number: 2536 • 2015 ACR/ARHP Annual Meeting
The Role of Race/Ethnicity and SES in Adverse Pregnancy Outcome in SLE and Apl
Sancia Ferguson¹, Elianna Kaplowitz², Laura Trupin³, Edward H. Yelin⁴, Patricia P. Katz^3,5 and Jane E. Salmon⁶, ¹Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ²Hospital for Special Surgery, New York, NY, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, UC San Francisco, San Francisco, CA, ⁵Arthritis Research Group, University of California San Francisco, San Francisco, CA, ⁶Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) and Anti-Phospholipid Antibodies (aPL) have pregnancies with higher rates of preterm labor, preeclampsia, and fetal loss than healthy…
Abstract Number: 2124 • 2015 ACR/ARHP Annual Meeting
Racial Disparities in Lupus Pregnancy
Megan E. B. Clowse¹ and Chad Grotegut², ¹Rheumatology & Immunology, Duke University, Durham, NC, ²Obstetrics & Gynecology, Duke University, Durham, NC
Background/Purpose: Both lupus and pregnancy have significant racial disparities, with black women experiencing higher rates of complication compared to other race and ethnic groups. …
Abstract Number: 2517 • 2015 ACR/ARHP Annual Meeting
Primary Sjögren’s Syndrome and Pregnancy: Evolution of Thyroid Function, Xerostomia, Xerophthalmia and Salivary Test for Dental Caries Risk
Elisa Trujillo¹, Maria del Mar Trujillo², Erica Padron³, Maria Garcia-Gonzalez⁴, Lorena Exposito⁵, Hiurma Sanchez⁵ and Sandra Garcia⁶, ¹Hospital Universitario de Canarias, Servicio de Reumatologia, Tenerife, Spain, ²Servicio Canario de Salud., Servicio de Evaluación de tecnología Sanitaria, santa cruz de Tenerife, Spain, ³Hospital Universitario de Canarias, Servicio de Ginecología y Obstetricia., santa cruz de Tenerife, Spain, ⁴Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Hospital Universitario de Canarias, Servicio de Reumatologia, santa cruz de Tenerife, Spain, ⁶Bow lane dental Group, Dentist, London, England
Background/Purpose: 1. To study the effect of pregnancy in PSS patients on oral and ocular dryness and the salivary test for dental caries activity. 2.…
Abstract Number: 1908 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes in the Tofacitinib RA Safety Database through April 2014
A. Marren¹, Y. Chen¹, D. Frazier² and J. Geier³, ¹Pfizer Inc, Collegeville, PA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Its effect in pregnant women is of interest, as tofacitinib…
Abstract Number: 1877 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes in SLE: Before and after
Elizabeth V. Arkema¹, Kristin Palmsten², Christopher Sjöwall³, Elisabet Svenungsson⁴, Jane E. Salmon⁵ and Julia F Simard⁶, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Pediatrics, University of California, San Diego, La Jolla, CA, ³Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA
Background/Purpose: Numerous investigators have demonstrated that the risks of pre-eclampsia, preterm delivery, and fetal death are increased in lupus pregnancies. Adverse events during pregnancy, delivery,…
Abstract Number: 1829 • 2014 ACR/ARHP Annual Meeting
Role of Fluorinated Steroids in Preventing the Progression of Anti-SSA/Ro Associated Isolated Congenital Heart Block to Disease Beyond the Conduction System
Ummara Shah¹, Amit Saxena¹, Sara Sahl², Deborah Friedman³, Jill P. Buyon¹ and Peter M. Izmirly², ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: The cardiac manifestations of neonatal lupus (cardiac NL) characteristically present as conduction disease. A major concern is the extension of injury beyond the AV…
Abstract Number: 1599 • 2014 ACR/ARHP Annual Meeting
Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Pregnancies: Disease Activity, Treatment, and Outcomes
Megan E. B. Clowse, Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: While it has long been reported that rheumatoid arthritis (RA) improves with pregnancy, there is very limited information about ankylosing spondylitis (AS) or…
Abstract Number: 1358 • 2014 ACR/ARHP Annual Meeting
A Systematic Analysis of the Safety of Prescribing Anti-Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women
Sonia Panchal¹, Julia Flint², Maud van de Venne³, Madeline Piper⁴, Alice Hurrel⁵, Joel Cunningham⁵, Mary Gayed⁶, Karen Schreiber⁷, Subha Anthanari⁸, Mohamed Nisar⁸, David Williams⁹, Munther Khamashta¹⁰, Caroline Gordon¹¹ and Ian Giles², ¹Rheumatology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom, ²UCL Division of Medicine, University College London, London, United Kingdom, ³Obstetrics and Gynaecology, North Bristol NHS Trust, Bristol, United Kingdom, ⁴Ysbyty Ystrad Fawr, Aneurin Bevan Health Board Wales, Wales, United Kingdom, ⁵Institute for Women's Health, University College London, London, United Kingdom, ⁶Rheumatology Division of Infection and Immunity, The Medical School, University of Birmingham, Birmingham, United Kingdom, ⁷Lupus Research Unit, Division of Infection and Immunity, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁸Rheumatology, Burton Hospitals NHS Foundation Trust, Burton-upon-Trent, United Kingdom, ⁹University College London, London, United Kingdom, ¹⁰Lupus Research Unit, Division of Women's Health, Guy's and St Thomas' NSH Foundation Trust, London, United Kingdom, ¹¹Rheumatology, Division of Infection and Immunity, The Medical School, University of Birmingham, Birmingham, United Kingdom
Background/Purpose The use of anti-rheumatic drugs in pregnancy is often complicated by concerns over their potential for adverse effects. Given that rheumatic diseases often affect…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].